Crescent Biopharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CBIO Nasdaq 2830 crescentbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Crescent Biopharma, Inc.

Crescent Biopharma to Present at November Investor Conferences - Nov 2nd, 2026 5:30 am
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001 - Oct 15th, 2026 2:15 pm
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors - Oct 5th, 2026 5:30 am
Crescent Biopharma Announces Grants of Inducement Awards - Sep 25th, 2026 2:15 pm
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold - Sep 3rd, 2026 2:51 pm
Crescent Biopharma to Present at September Investor Conferences - Sep 3rd, 2026 5:30 am
Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Jul 30th, 2026 5:35 am
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Jul 16th, 2026 2:01 pm
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants - Jul 14th, 2026 7:45 pm
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants - Jul 14th, 2026 2:01 pm